Check 35,000+ stocks against 26 valuation models and 37 quality factors

Simcere Pharmaceutical Group Limited (SMHGF) fair value: what the stock is really worth

As of Sep 25, 2026: fair value of Simcere Pharmaceutical Group Limited $1.49, price $1.35, upside +10.0%, quality 65 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

Fair value above price? Yes
Good quality? Yes
Add to watchlist

Healthcare · US · Home Hong Kong

Broad data Sep 24, 2026

Simcere Pharmaceutical Group Limited

SMHGF · US

NeutralQuality growthThe stock looks roughly fairly valued with average quality.

·Fair value $1.49 · Fairly valued (+10.0%)

✓Quality 65/100

✓Healthy Growth (revenue 5y +11.4 %/yr)

✓Solidly profitable · 17.4% net margin (TTM)

✓Low debt · generates free cash flow

✓13.3% dividend yield · Well covered

✓Ranks above peers (10/14)

!Moderate moat 57/100

!Insider activity 40/100

26 models, one by oneBear $1.04 to bull $1.93 Growth analysisrevenue history, year by year Quality 65/100 in detail37 factors, each one shown Compared with its peersrank on every measure, side by side

Watch Simcere Pharmaceutical Group Limited for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.

How to read this chart

32‑month range $0.6371 – $1.93 · fair‑value band $1.04 – $1.93 · the $1.35 price screens below the $1.49 fair value. Dashed = 300-day average. As of Sep 24, 2026.

Follow Simcere Pharmaceutical Group in your weekly email

Every Wednesday you see whether Simcere Pharmaceutical Group is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Simcere Pharmaceutical Group Limited, an investment holding company, engages in the research, development, manufacture, and sale of pharmaceutical products to distributors, pharmacy chains, and other pharmaceutical manufacturers in China. It develops Endostar, a recombinant human endostatin injection; ENWEIDA, an envafolimab injection; Leruiping, a fully human monoclonal antibody targeting IL-4Ra; Zemprocitinib a highly selective JAK1 inhibitor; and Xianlinda, an inhibitor for influenza polymerase acidic protein that has completed Phase 3 clinical trials. The company also develops SIM0270, a new-generation oral SERD with blood-brain barrier penetration characteristics; Denlorlatinib; SIM0395, a BBB-penetrant inhibitor of the PI3K/mTOR pathway; and deuterated remdesivir hydrobromide dry suspension that are in Phase 3 clinical trial, as well as Sanbexin an injection new indication; Sanbexin a sublingual tablets; and SIM0278, a Fc fusion protein (IL2muFc) with an IL2 mutein of regulatory T cells that is in Phase 2 clinical trials. It develops SIM0237, an anti-PD-L1 monoclonal antibody fused with IL-15/IL15RXa sushi protein; Enzeshu, a suvemcitug for injection; SIM0500, a humanized trispecific antibody that targets GPRC5D/BCMA/CD3; SIM0508, a small molecule inhibitor; SIM0505, a CDH6-targeting ADC molecule; SIM0686, an ADC drug targeting FGFR2b; SIM0609, a new antibody-drug conjugate targeting CDH17; SIM0610, a bispecific antibody-drug conjugate; SIM0532, an oral, non-covalent pan-RAS inhibitor; SIM0323; and SIM0811, a small-molecule plasminogen allosteric activator that are in Phase 1 clinical trial. The company develops SIM0613; SIM0709; SIM0689; SIM0688; SIM0518; SIM0616; SIM0611; SIM0815; SIM0712; SIM0725; SIM0708; SIM0721; and SIM0722 that are in pre-clinical stage. It offers pharmaceutical ingredients; production support facility; consulting and technology; promotion; and property management. The company was founded in 1995 and is headquartered in Nanjing, China.

Stock analysis

Simcere Pharmaceutical Group Limited (SMHGF) currently trades at $1.35, while our model-based Fair Value estimate is $1.49, implying the stock looks roughly 9.1% undervalued today.

Valuation

Bull case: the DCF Models group reads highest at a median of $1.65 per share, and 14 of the 24 models we run sit above the $1.35 price.

Bear case: the Asset-Based group reads lowest at $0.3700, and 10 of the 24 models stay below the price. Evidence for this calculation is high.

Scenario range: $1.04 (bear) to $1.93 (bull), the price of $1.35 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 65/100 (solid quality), in the Healthcare sector.

Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.

Simcere Pharmaceutical Group Limited reported revenue of 7.7B CNY in FY2025 versus 5.0B CNY in FY2021, a compound +11.5%/yr. Reported net income was 1.3B CNY in FY2025, compounding −2.8%/yr from FY2021.

Key figures

Market cap $3.8B · P/E ratio 16.9 · P/S ratio 2.93 · EPS (TTM) $0.0800 · Dividend yield 13.3% · Net margin 17.4% · Return on equity 16.2% · Return on assets (EBIT) 6.5%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 42 out of 100 (medium confidence).

What moves the price

The share trades about 30% below its 52-week high and 99% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −19% fair-value upside, at 10%, SMHGF screens cheaper than that median.

Fair Value models

Bear $1.04 Fair Value $1.49 Bull $1.93

Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.

Highest evidence

FCF DCF $1.05 $1.65 $2.63 79

Growth DCF $1.05 $1.60 $2.48 77

Owner Earnings $0.8500 $1.31 $2.06 75

All 24 models by family

DCF Models

FCF DCF $1.05 $1.65 $2.63 79

Owner Earnings $0.8500 $1.31 $2.06 75

5Y Revenue Exit $0.9700 $1.50 $2.21 72

5Y EBITDA Exit $1.14 $1.86 $2.74 74

5Y P/E Exit $1.27 $2.11 $3.05 70

10Y Revenue Exit $0.9700 $1.47 $2.22 66

10Y EBITDA Exit $1.10 $1.72 $2.64 67

10Y P/E Exit $1.18 $1.90 $2.89 63

Earnings-Based

Graham-Dodd $0.5300 $2.28 $3.12 64

Lynch FV $0.5800 $0.8400 $1.09 61

PEG = 1.0 $0.5800 $0.8400 $1.09 57

EPV $0.7900 $0.8800 $0.9600 71

Multiples

P/E Multiple $1.29 $1.72 $2.15 63

P/S Multiple $1.00 $1.33 $1.66 58

P/B Multiple $1.00 $1.33 $1.66 55

EV/EBIT $1.24 $1.58 $1.93 66

EV/EBITDA $1.29 $1.65 $2.01 67

EV/Revenue $0.9400 $1.26 $1.57 54

Asset-Based

NCAV (Graham) $0.2700 $0.3700 $0.5500 54

Growth DCF

Growth DCF $1.05 $1.60 $2.48 77

Rev-Margin DCF $0.9700 $1.49 $2.15 72

Economic Profit

Residual Income $0.5300 $0.6700 $0.9800 75

ROIC Compounder $0.8500 $1.06 $1.32 72

Growth Earnings

Growth-Adj P/E $1.01 $1.44 $1.87 67

Open the full fair value analysis →

Notify me when SMHGF reaches fair value

Put SMHGF on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 65/100

Of which business quality 66 · Market factors (momentum, volatility) 54

Profitability 60

Margins and returns on capital today

Quality Growth 60

Are margins and returns improving?

Cashflow 65

Earnings quality: real cash, not paper profit

Fin. Strength 83

Balance sheet, leverage, solvency risk

Investment 49

Disciplined investing over empire-building

Low Volatility 45

Calm price path (market factor)

Momentum 47

Price trend over the last 3–12 months (market factor)

52W Momentum 77

Distance to the 52-week high (market factor)

Net Issuance 73

Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 94/100

Revenue growth appears healthy and is supported by profitability and cash-flow quality.

Revenue growth 1 year

+16.5%

Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.

+6.9%

Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.

+11.4%

Start year 2020 (pandemic)

’20

’21

’22

’23

’24

’25

What shareholders gained per year (last 5 years) (mathematically smoothed) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Smoothed = median of all growth paths between the years of the window (trend line on the logarithm of earnings per share): a single extreme year cannot distort the rate. The reported figure stays in the tooltip.

+16.0%

Earnings growth per share plus dividend.

Earnings per share, growth per year+2.7%

Dividend (yield on the price)13.3%

Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.13% → 18%

2025 sits 82% above its own trend. The rate follows the median trend of the last 5 years, not that single year.

Growth Forecast

Little optimism in the price

The price assumes less growth than the company has delivered so far.

What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).

+5.6%

Yearly growth needed for the next five years to justify today's price.

What forecasts expect

n/a

No analyst forecast available.

After inflation (figures in CNY, China: IMF forecast 1.7% a year to 2030, 1.4% from 2016 to 2025) that is about +3.9% a year for the price.

Watch SMHGF, get fair value alerts →

Compare Simcere Pharmaceutical Group Limited with another stock

Price, fair value, quality and upside side by side.

First stock

Second stock

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 599 stocks

Beats the industry median on 10/14 measures

Overall it ranks above its industry peers.

Valuation

Quality Score 65 · Top 25%

Fair Value upside +13.7% · Above median

Profitability

Return on equity (TTM) 16.2% · Top 25%

Return on assets 6.7% · Top 25%

Net margin (TTM) 17.4% · Top 25%

Operating margin (TTM) 17.0% · Above median

Growth and dividend

Revenue growth 17.7% · Above median

Dividend yield (TTM) 13.3% · Top 25%

Balance sheet

Debt / equity 0.00× · Lowest 25%

Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper

P/E (TTM) 16.9× · Cheaper than median

P/B 2.72× · Pricier than median

P/S (TTM) 3.31× · Pricier than median

P/FCF 22.3× · Pricier than median

EV/EBITDA 12.9× · Pricier than median

Strength profile in five axes (Snowflake)

This stock

Sector peers

VALUE (fair-value potential)52 · sector 17

FUTURE (revenue growth)89 · sector 24

PAST (return on equity)65 · sector 27

HEALTH (low debt)100 · sector 96

DIVIDEND (yield)100 · sector 30

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate.

Stock	Price	Fair Value	vs Fair Value
Merck KGaA MRK	€134.45	€108.94	−19%
Takeda Pharmaceutical Company TAK	$18.90	$11.45	−39%
Teva Pharmaceutical Industries Limited TEVA	$39.31	$20.88	−47%
Sun Pharmaceutical Industries Limited SUNPHARMA	₹1,852	₹1,979	+7%
Galderma Group GALD	CHF 163.00	CHF 110.32	−32%
Jiangsu Hengrui Pharmaceuticals Co 600276	¥44.86	¥49.35	+10%
Haleon plc HLN	$9.26	$8.49	−8%
Sandoz Group SDZ	CHF 71.16	CHF 40.32	−43%
Zoetis Inc ZTS	$70.30	$110.50	+57%
Divi's Laboratories Limited DIVISLAB	₹9,620	₹1,871	−81%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks Technology Financial Services Healthcare Consumer Cyclical Consumer Defensive Communication Services Industrials Energy Basic Materials Real Estate Utilities Deeply Undervalued Stocks Undervalued High-Quality Stocks Undervalued Blue-Chip Stocks Undervalued Small-Cap Stocks Undervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark

Run the numbers yourself: free valuation calculators

DCF Calculator Graham Number Peter Lynch Formula DDM Calculator Fama-French Model Intrinsic Value

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Simcere Pharmaceutical Group Limited · Fair Value
$1.49 +9%Fair Value
Calculator →

<a href="https://www.fairvalue-calculator.com/stock/SMHGF" target="_blank" rel="nofollow noopener" style="display:inline-flex;align-items:center;gap:12px;box-sizing:border-box;font-family:system-ui,-apple-system,Segoe UI,Roboto,sans-serif;text-decoration:none;background:#0f1814;color:#eaf2ed;border:1px solid #2a3a30;border-radius:12px;padding:12px 16px;max-width:360px"><span style="line-height:1.35"><span style="font-size:12px;color:#9fb0a8">Simcere Pharmaceutical Group Limited · Fair Value</span><br><b style="font-size:20px">$1.49</b> <span style="color:var(--fvc-g-mitte);font-weight:700;font-size:14px">+9%</span></span><span style="font-size:11px;color:var(--fvc-g-mitte);font-weight:700;margin-left:auto;text-align:right;line-height:1.3">Fair&nbsp;Value<br>Calculator&nbsp;→</span></a>

Cite: Fair Value Calculator (2026). "Simcere Pharmaceutical Group Limited Fair Value". https://www.fairvalue-calculator.com/stock/SMHGF

Frequently asked questions

Is Simcere Pharmaceutical Group Limited (SMHGF) overvalued or undervalued?

As of Sep 24, 2026, our model estimates a fair value of $1.49 versus the last price from Sep 25, 2026 of $1.35, about +10% upside (undervalued).

What is the fair value of SMHGF?

Our model-based fair value for Simcere Pharmaceutical Group Limited is $1.49 (as of Sep 24, 2026), built from audited fundamentals. Last price (from Sep 25, 2026): $1.35.

What is the quality score of SMHGF?

Simcere Pharmaceutical Group Limited has a Quality Score of 65/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.

What is the price target for Simcere Pharmaceutical Group Limited (SMHGF)?

Our model-based price target is the fair value of $1.49 (as of Sep 24, 2026) from 24 valuation models. Cautious scenario $1.04, optimistic scenario $1.93. It is a calculation from audited fundamentals, not an analyst target.

What is the Simcere Pharmaceutical Group Limited stock forecast for 2026?

Our models put fair value at $1.49, about +10% upside versus the last price from Sep 25, 2026 of $1.35 (undervalued). Cautious scenario $1.04, optimistic scenario $1.93. The calculation is refreshed regularly with new filings.

What is the revenue of Simcere Pharmaceutical Group Limited (SMHGF)?

Simcere Pharmaceutical Group Limited reported trailing-twelve-month revenue of about 7.7B CNY (latest available figure, as of Sep 24, 2026).

Does Simcere Pharmaceutical Group Limited pay a dividend?

Simcere Pharmaceutical Group Limited currently shows a dividend yield of about 13.33% relative to its recent price (as of Sep 24, 2026).

What growth is priced into Simcere Pharmaceutical Group Limited (SMHGF)?

For today's price to be fair in a discounted-cash-flow model, Simcere Pharmaceutical Group Limited would have to grow free cash flow by +5.6 % per year for five years (discount rate 8.9 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +11.4 % per year. As of Sep 24, 2026.

What discount rate (WACC) does the fair value of SMHGF use?

Our models discount Simcere Pharmaceutical Group Limited at 8.9 %: a base by market capitalisation (mid), damped by beta 0.64, country premium for USA. The same rate applies in all 26 models.

What is a reverse DCF?

A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Simcere Pharmaceutical Group Limited that is +5.6 % per year a year over ten years, using the same discount rate (8.9 %) and the same formula as our fair value.

How much growth has Simcere Pharmaceutical Group Limited (SMHGF) delivered so far?

Over the past 5 years revenue at Simcere Pharmaceutical Group Limited grew +11.4 % a year. The price currently implies +5.6 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.

How fast is the sector of Simcere Pharmaceutical Group Limited (SMHGF) growing?

The median revenue growth in the sector is +1.7 % a year. That is the yardstick for the growth priced into Simcere Pharmaceutical Group Limited (+5.6 % per year a year): it shows whether the expectation is within the usual range or beyond it.

What is the free cash flow yield of Simcere Pharmaceutical Group Limited (SMHGF)?

The free-cash-flow yield on the price is 4.91 %: that much free cash flow Simcere Pharmaceutical Group Limited produces per unit of market value. When it exceeds the discount rate of our models (8.9 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.

What is the intrinsic value of Simcere Pharmaceutical Group Limited (SMHGF)?

Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Simcere Pharmaceutical Group Limited it is $1.49 per share (as of Sep 24, 2026), against a price of $1.35. It is the blended result of 24 valuation models (cash flow, earnings, asset, dividend).

Is Simcere Pharmaceutical Group Limited stock overvalued or undervalued in 2026?

As of Sep 24, 2026, SMHGF trades below its calculated fair value: price $1.35, fair value $1.49, a gap of about +10% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.

Is fair value the same as the market price of SMHGF?

No. The price is what the market pays today ($1.35); the fair value is what the company's own numbers justify ($1.49). For Simcere Pharmaceutical Group Limited the two are $0.1350 per share apart. That gap is exactly why we show both numbers side by side.

How much is Simcere Pharmaceutical Group Limited worth?

The market values Simcere Pharmaceutical Group Limited at about $3.8B (market capitalisation, as of Sep 24, 2026). Per share that is $1.35; our models calculate a fair value of $1.49 per share.

What do the bullish and bearish scenarios say about SMHGF?

Our models span a range for Simcere Pharmaceutical Group Limited: cautious scenario $1.04, base $1.49, optimistic $1.93 per share (as of Sep 24, 2026, price $1.35). The range comes from different growth and margin assumptions, not from analyst opinions.

What is the P/E ratio of SMHGF?

Simcere Pharmaceutical Group Limited trades at a price-to-earnings ratio of 16.9 (as of Sep 24, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of $1.49 is built from several models across several years. Other multiples: P/B 2.7, P/S 3.3, EV/EBITDA 12.9.

How solid is the balance sheet of Simcere Pharmaceutical Group Limited (SMHGF)?

Balance-sheet figures for Simcere Pharmaceutical Group Limited (as of Sep 24, 2026): return on equity 16.2%, debt of 0.00 per unit of equity. They feed the Quality Score of 65/100, which measures business quality independently of the share price.

How far is SMHGF from its 52-week high?

Simcere Pharmaceutical Group Limited trades at $1.35, about 30% below its 52-week high of $1.93 and 99% above the low of $0.6799 (as of Sep 25, 2026). Distance from the high says nothing about value: that is what the fair value of $1.49 is for.

Which stocks are comparable to Simcere Pharmaceutical Group Limited?

From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Teva Pharmaceutical Industries Limited, Sun Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.

Is Simcere Pharmaceutical Group Limited stock attractive at the current price?

The data as of Sep 24, 2026: price $1.35, calculated fair value $1.49 (+10%), Quality Score 65/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.

How is the fair value of SMHGF calculated?

We run Simcere Pharmaceutical Group Limited through 24 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $1.49, with the spread shown as a cautious and an optimistic scenario.

Is it still worth investing in stocks now?

The global stock market currently sits 14.5 % above its aggregate fair value. Simcere Pharmaceutical Group Limited currently trades 9 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.

What is the share price of Simcere Pharmaceutical Group Limited (SMHGF)?

The latest price we hold is from Sep 25, 2026 and stands at $1.35. Our model-based fair value is $1.49, about +10% upside (undervalued). We carry closing prices from our data provider, not a live tick.

What should I pay attention to with Simcere Pharmaceutical Group Limited right now?

A fairly wide model range ($1.04 to $1.93) leaves room in how you read the outcome. The price sits in the lower half of our model range, the side with the larger margin of safety. The data supports the verdict: every model runs on fully documented inputs.

Key figures of Simcere Pharmaceutical Group Limited

How large is the market capitalisation of Simcere Pharmaceutical Group Limited (SMHGF)?

The market capitalisation of Simcere Pharmaceutical Group Limited is $3.8B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.

What is the P/S ratio of Simcere Pharmaceutical Group Limited (SMHGF)?

The price-to-sales ratio of Simcere Pharmaceutical Group Limited is 2.93 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.

What are the earnings per share of Simcere Pharmaceutical Group Limited (SMHGF)?

Earnings per share at Simcere Pharmaceutical Group Limited are $0.0800 (price ÷ EPS = P/E 16.9). Earnings per share over the last twelve months: total profit spread across every single share.

What is the dividend yield of Simcere Pharmaceutical Group Limited (SMHGF)?

The dividend yield of Simcere Pharmaceutical Group Limited is 13.3%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.

What is the net margin of Simcere Pharmaceutical Group Limited (SMHGF)?

The net margin of Simcere Pharmaceutical Group Limited is 17.4% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.

What is the return on equity of Simcere Pharmaceutical Group Limited (SMHGF)?

The return on equity (ROE) of Simcere Pharmaceutical Group Limited is 16.2% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.

What is the EBIT return on assets of Simcere Pharmaceutical Group Limited (SMHGF)?

On an EBIT basis the return on assets of Simcere Pharmaceutical Group Limited is 6.5% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.

What is the operating margin of Simcere Pharmaceutical Group Limited (SMHGF)?

The operating margin of Simcere Pharmaceutical Group Limited is 17.0% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.

How fast is revenue growing at Simcere Pharmaceutical Group Limited (SMHGF)?

Revenue at Simcere Pharmaceutical Group Limited is growing +17.7% versus a year earlier (3y avg +6.9%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.

How fast are earnings growing at Simcere Pharmaceutical Group Limited (SMHGF)?

Earnings per share at Simcere Pharmaceutical Group Limited are growing +170% versus a year earlier. How much earnings per share grew versus a year earlier.

How much net debt does Simcere Pharmaceutical Group Limited (SMHGF) carry?

The net debt of Simcere Pharmaceutical Group Limited is 557M CNY (fiscal year 2021, ≈ 0.5 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.

Free · no account needed

Watch Simcere Pharmaceutical Group Limited in the live analysis

One click puts Simcere Pharmaceutical Group Limited on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.